Computer analysis of maternal-fetal heart rate recordings during labor in relation with maternal-fetal attachment and prediction of newborn acidemia

Computerized analysis of cardiotocograms in clinical practice and the SisPorto® system thirty-two years after: technological, physiopathological and clinical studies

OBJECTIVES

The objective of this study is to present the why, what and how about computerized analysis of cardiotocograms (cCTG) and the SisPorto system for cCTG.

CONTENT

A narrative review about cCTG and the SisPorto system for cCTG is presented. The meta-analysis of randomized controlled trials (RCT) performed so far have evidenced that cCGT compared to traditional CTG analysis may save time spent in hospital for women, in the antepartum period, and is objective with at least equivalent results in maternal and perinatal outcomes, both in the ante and intrapartum periods. The SisPorto system for cCTG closely follows the FIGO guidelines for fetal monitoring. It may be used both in the ante and intrapartum periods, alone or connected to a central monitoring station, with simultaneous monitoring of fetal and maternal signals, not only in singletons but also in twins. It has been assessed in technical, physiopathological and clinical studies, namely in one large multicentric international RCT during labor and two meta-analysis.

SUMMARY AND OUTLOOK

There is evidence that cCTG may be useful in clinical practice with advantages compared to traditional CTG analysis, although without clear impact on the decrease of preventable maternal and perinatal mortality and morbidity. More studies are warranted, namely on technical improvements and assessment in larger studies in a wider range of clinical settings.

Technical Update No. 429: Maternal Heart Rate Artefact During Intrapartum Fetal Health Surveillance

OBJECTIVE

To improve perinatal outcomes and minimize provider error by increasing awareness of strategies to detect intrapartum maternal heart rate artefact and to respond when such artefact is suspected.

TARGET POPULATION

All pregnant patients during labour.

OPTIONS

Maternal heart rate artefact may be detected based on clinical features or through technology. Suspected maternal heart rate artefact may be assessed by applying a fetal scalp electrode (preferred) or through external fetal monitoring, augmented by point-of-care sonography (alternative).

OUTCOMES

Unrecognized intrapartum maternal heart rate artefact increases the risk that abnormal/atypical fetal heart rate patterns will go undetected and, hence, the risk of adverse perinatal outcomes.

BENEFITS, HARMS, AND COSTS

Unrecognized maternal heart rate artefact can lead to adverse perinatal outcomes (hypoxic-ischemic encephalopathy, fetal death, and neonatal death) and adverse maternal outcomes (unnecessary cesarean delivery or operative vaginal delivery). Timely recognition of such artefact may avoid these adverse outcomes. The costs of early recognition of maternal heart rate artefact are relatively small: increased use of fetal scalp electrodes and point-of-care sonography, as well as additional assessments by the health care provider. The cost savings are significant, as a result of lower risk of adverse perinatal outcomes. Potential harms are false-positive diagnoses of maternal heart rate artefact, expediting delivery unnecessarily when the fetal status cannot be reliably determined but is normal, and the rare complications associated with increased use of fetal scalp electrodes.

EVIDENCE

Two PubMed searches were completed. The first was for articles published between January 1, 1970, and November 25, 2021, using the medical subject headings (MeSH) "fetal monitoring" and "artifacts" (38 articles). The second was for articles published during the same period using the MeSH "fetal monitoring" and "maternal heart rate" (841 articles).

VALIDATION METHODS

The authors rated the quality of evidence and strength of recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. See online Appendix A (Tables A1 for definitions and A2 for interpretations of strong and conditional [weak] recommendations).

INTENDED AUDIENCE

All health care providers involved in obstetrical care.

SUMMARY STATEMENTS

RECOMMENDATIONS.

Mise à jour technique no 429 : Artéfact de la fréquence cardiaque maternelle pendant la surveillance du bien-être fœtal per partum

OBJECTIF

Améliorer les issues périnatales et réduire au minimum le risque d'erreurs chez les fournisseurs en améliorant leurs connaissances sur les stratégies de détection des artéfacts de la fréquence cardiaque maternelle per partum et sur les modes d'intervention lorsque de tels artéfacts sont soupçonnés.

POPULATION CIBLE

Toutes les parturientes.

OPTIONS

L'artéfact de la fréquence cardiaque maternelle peut être détecté à l'aide de caractéristiques cliniques ou de la technologie. On peut évaluer l'artéfact de la fréquence cardiaque maternelle soupçonné en posant une électrode de cuir chevelu fœtal (option à privilégier) ou en recourant à la surveillance fœtale externe optimisée par l'échographie au chevet (solution de rechange). RéSULTATS: Les artéfacts de la fréquence cardiaque maternelle per partum non détectés augmentent le risque que des rythmes anormaux ou atypiques de la fréquence cardiaque fœtale passent inaperçus, ce qui augmente le risque d'issues périnatales défavorables. BéNéFICES, RISQUES ET COûTS: L'artéfact de la fréquence cardiaque maternelle non détecté peut entraîner de graves issues périnatales défavorables (encéphalopathie hypoxo-ischémique, mort fœtale et mort néonatale) et des issues maternelles défavorables (césarienne injustifiée ou accouchement assisté). Ces issues peuvent être évitées par la détection rapide d'un tel artéfact. Le coût de la détection précoce des artéfacts de fréquence cardiaque maternelle est relativement faible (utilisation accrue des électrodes de cuir chevelu fœtal et de l'échographie au chevet avec évaluations supplémentaires par le fournisseur de soins). La réduction des événements périnataux défavorables engendre des économies considérables. Les risques sont : faux positifs d'artéfact de la fréquence cardiaque maternelle; accélération inutile de l'accouchement lorsque l'état du fœtus est normal, mais qu'on ne peut le déterminer de façon fiable; et les rares complications associées à l'utilisation accrue des électrodes de cuir chevelu fœtal. DONNéES PROBANTES: Deux recherches ont été effectuées dans PubMed. La première a été réalisée pour répertorier les articles publiés entre le 1^er janvier 1970 et le 25 novembre 2021 à partir des termes MeSH fetal monitoring et artifacts (38 articles); la deuxième, pour répertorier les articles publiés au cours de la même période à partir des termes MeSH fetal monitoring et maternal heart rate (841 articles). MéTHODES DE VALIDATION: Les auteurs ont évalué la qualité des données probantes et la force des recommandations en utilisant le cadre méthodologique GRADE (Grading of Recommendations, Assessment, Development, and Evaluation). Voir l'annexe A en ligne (tableau A1 pour les définitions et tableau A2 pour l'interprétation des recommandations fortes et conditionnelles [faibles]). PROFESSIONNELS CONCERNéS: Tous les fournisseurs de soins obstétricaux. DÉCLARATIONS SOMMAIRES: RECOMMANDATIONS.

Unrecognized maternal heart rate artefact in cases of perinatal mortality reported to the United States Food and Drug Administration from 2009 to 2019: a critical patient safety issue

BACKGROUND

Maternal heart rate artefact is a signal processing error whereby the fetal heart rate is masked by the maternal pulse, potentially leading to danger by failure to recognize an abnormal fetal heart rate or a pre-existing fetal death. Maternal heart rate artefact may be exacerbated by autocorrelation algorithms in modern fetal monitors due to smooth transitions between maternal and fetal heart rates rather than breaks in the tracing. In response, manufacturers of cardiotocography monitors recommend verifying fetal life prior to monitoring and have developed safeguards including signal ambiguity detection technologies to simultaneously and continuously monitor the maternal and fetal heart rates. However, these safeguards are not emphasized in current cardiotocography clinical practice guidelines, potentially leading to a patient safety gap.

METHODS

The United States Food and Drug Administration Manufacturer and User Facility Device Experience database was reviewed for records with event type "Death" for the time period March 31, 2009 to March 31, 2019, in combination with search terms selected to capture all cases reported involving cardiotocography devices. Records were reviewed to determine whether maternal heart rate artefact was probable and/or whether the report contained a recommendation from the device manufacturer regarding maternal heart rate artefact.

RESULTS

Forty-seven cases of perinatal mortality were identified with probable maternal heart rate artefact including 14 with antepartum fetal death prior to initiation of cardiotocography, 14 with intrapartum fetal death or neonatal death after initiation of cardiotocography, and 19 where the temporal relationship between initiation of cardiotocography and death cannot be definitively established from the report. In 29 cases, there was a recommendation from the manufacturer regarding diagnosis and/or management of maternal heart rate artefact.

CONCLUSIONS

This case series indicates a recurring problem with undetected maternal heart rate artefact leading to perinatal mortality and, in cases of pre-existing fetal death, healthcare provider confusion. In response, manufacturers frequently recommend safeguards which are found in their device's instructions for use but not in major intrapartum cardiotocography guidelines. Cardiotocography guidelines should be updated to include the latest safeguards against the risks of maternal heart rate artefact. An additional file summarizing key points for clinicians is included.

A Comprehensive Evaluation of the Predictive Abilities of Fetal Electrocardiogram-Derived Parameters during Labor in Newborn Acidemia: Our Institutional Experience

This study aimed to identify cardiotocography patterns that discriminate fetal acidemia newborns by comprehensively evaluating the parameters obtained from Holter monitoring during delivery. Between June 1, 2015, and August 1, 2016, a prospective observational study of 85 patients was conducted using fetal Holter monitoring at the Beijing Obstetrics and Gynecology Hospital, Capital Medical University, China. Umbilical cord blood was sampled immediately after delivery and fetal acidemia was defined as umbilical cord arterial blood pH < 7.20. Fetal electrocardiogram- (FECG-) derived parameters, including basal fetal heart rate (BFHR), short-term variation (STV), large acceleration (LA), deceleration capacity (DC), acceleration capacity (AC), proportion of episodes of high variation (PEHV), and proportion of episodes of low variation (PELV), were compared between 16 fetuses with acidemia and 47 without. The areas under the curve (AUC) of receiver operating characteristics (ROC) were calculated. Although all the computerized parameters showed predictive values for acidemia (all AUC > 0.50), STV (AUC = 0.84, P < 0.001), DC (AUC = 0.84, P < 0.001), AC (AUC = 0.80, P < 0.001), and PELV (AUC = 0.71, P = 0.012) were more strongly associated with fetal acidemia. Our institutional experience suggests that FECG-derived parameters from Holter monitoring are beneficial in reducing the incidence of neonatal acidemia.

Evolution of linear and nonlinear fetal heart rate indices throughout pregnancy in appropriate, small for gestational age and preterm fetuses: A cohort study

BACKGROUND AND OBJECTIVES

To assess the evolution of linear and nonlinear fetal heart rate (FHR) analysis throughout pregnancy in appropriate (AGA), small for gestational age (SGA) and preterm (PTB) fetuses.

METHODS

A prospective cohort study was carried out in 171 singleton pregnancies divided in three groups: AGA (n = 147), SGA (n = 13) fetuses and spontaneous PTB (n = 11). FHR was recorded with an external sensor from the 24th to the 40th week of gestation. Linear time- and frequency-domain and nonlinear FHR indices were computed on 10-min segments. Longitudinal analysis of indices throughout pregnancy was performed with generalized estimating equations, and receiver operating characteristic (ROC) curves were calculated for the prediction of SGA and PTB fetuses.

RESULTS

Increasing gestational age significantly affected most FHR indices, with a general increase in variability and entropy indices, and a decrease in mean FHR. The PTB group exhibited a significantly lower short-term variation, and no monotonic increase in the sympatho-vagal balance as observed in the AGA group. The SGA group exhibited higher long-term irregularity and lower short-term irregularity than the AGA group throughout gestation. In prediction of SGA and PTB, the largest areas under the ROC curves obtained were 0.76 and 0.78, respectively.

CONCLUSIONS

Linear and nonlinear FHR analysis provides useful information on the evolution of fetal autonomic nervous and complexity control systems throughout pregnancy, in relation with AGA, SGA and PTB fetuses, which may be helpful in clinical practice.

Simultaneous monitoring of maternal and fetal heart rate variability during labor in relation with fetal gender

Male gender is considered a risk factor for several adverse perinatal outcomes. Fetal gender effect on fetal heart rate (FHR) has been subject of several studies with contradictory results. The importance of maternal heart rate (MHR) monitoring during labor has also been investigated, but less is known about the effect of fetal gender on MHR. The aim of this study is to simultaneously assess maternal and FHR variability during labor in relation with fetal gender. Simultaneous MHR and FHR recordings were obtained from 44 singleton term pregnancies during the last 2 hr of labor (H_1, H₂ ). Heart rate tracings were analyzed using linear (time- and frequency-domain) and nonlinear indices. Both linear and nonlinear components were considered in assessing FHR and MHR interaction, including cross-sample entropy (cross-SampEn). Mothers carrying male fetuses (n = 22) had significantly higher values for linear indices related with MHR average and variability and sympatho-vagal balance, while the opposite occurred in the high-frequency component and most nonlinear indices. Significant differences in FHR were only observed in H₁ with higher entropy values in female fetuses. Assessing the differences between FHR and MHR, statistically significant differences were obtained in most nonlinear indices between genders. A significantly higher cross-SampEn was observed in mothers carrying female fetuses (n = 22), denoting lower synchrony or similarity between MHR and FHR. The variability of MHR and the synchrony/similarity between MHR and FHR vary with respect to fetal gender during labor. These findings suggest that fetal gender needs to be taken into account when simultaneously monitoring MHR and FHR.